Dawnrays Biotechnology Capital (Asia)

Dawnrays Biotechnology Capital (Asia) is a Hong Kong-incorporated subsidiary of Dawnrays Pharmaceutical focused on investing in and developing biotech projects. Public disclosures describe its principal areas of interest as oncology and cardiovascular disease. Its most visible asset has been its former 35% stake in AD Pharmaceuticals, a joint venture with Akeso centered on the PCSK9 monoclonal antibody ebronucimab. In February 2024, Dawnrays agreed to transfer that stake to Akeso Biopharma, meaning the company appears to function primarily as a strategic investment and development vehicle rather than a fully integrated operating biotech with a broad standalone pipeline. Based on available public information, its direct drug-development footprint is limited and closely tied to the AD Pharmaceuticals/ebronucimab program.